LUCD · Lucid Diagnostics Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the accompanying unaudited condensed consolidated financial statements are issued.”View the 10-Q filed Aug 12, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $5.45M | $4.71M | $4.35M | $2.43M | $377K | $500K | — | |
| — | $6.67M | $7.1M | — | $100M | $585K | — | |
| — | — | — | — | $377K | $500K | — | |
| — | — | — | — | 100% | 100% | — | |
| $5.39M | $5.68M | $5.99M | $7.25M | $11.26M | $9.3M | $5.44M | |
| $20.41M | $17.71M | $16.46M | $16.4M | $16.13M | $5.26M | $1.31M | |
| $23.28M | $23.87M | $20.16M | $19.25M | $23.97M | $12.78M | $1.53M | |
| — | — | — | — | — | $21K | $7000 | |
| $421K | $421K | $688K | $2.02M | $1.65M | $0 | — | |
| $875K | $872K | $1.17M | $2.5M | $1.94M | $4000 | — | |
| $52.4M | — | $50.4M | $50.91M | $56.63M | $27.92M | $8.28M | |
| — | $54.35M | $50.4M | — | — | — | — | |
| -$50.68M | -$49.64M | -$46.05M | -$48.48M | -$56.25M | -$27.42M | -$8.28M | |
| — | -1054.82% | -1059.64% | -1996.79% | -14920.69% | -5483.8% | — | |
| -$49.81M | -$48.77M | -$44.89M | -$45.98M | -$54.32M | -$27.42M | — | |
| $17K | $22K | $26K | $416K | $8000 | — | — | |
| — | $386K | $322K | — | — | — | — | |
| -$1.58M | -$8.37M | $523K | -$4.18M | $80K | -$659K | — | |
| -$52.26M | -$58.01M | -$45.53M | -$52.67M | -$56.17M | -$28.08M | -$8.28M | |
| — | $0 | $0 | — | — | — | — | |
| -$52.26M | -$58.01M | -$45.53M | -$52.67M | -$56.17M | -$28.08M | -$8.28M | |
| — | -1232.68% | -1047.61% | -2169.11% | -14899.47% | -5615.6% | — | |
| -$65.01M | -$70.57M | -$53.03M | -$52.67M | — | — | — | |
| USD/shares | -$0.34 | -$0.69 | -$1.05 | -$1.26 | -$1.55 | -$1.51 | — |
| USD/shares | -$0.87 | — | -$1.05 | -$1.26 | -$1.55 | — | — |
| shares | — | 101.95M | 50.52M | 41.76M | 36.17M | 18.6M | 14.11M |
| shares | — | — | 50.52M | 41.76M | 36.17M | 18.6M | 14.11M |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 83 similar-size Medical Devices companies (of 150 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2022 |
|---|---|
| EsoGuard Test | $188,000 |